Search for Clinical Trial Results

Mantle Cell Lymphoma - 23 Studies Found
Status | Study |
Completed |
Study Name: Study of Mantle Cell Lymphoma Treatment by RiBVD Condition: Mantle Cell Lymphoma Date: 2011-10-20 Interventions: Drug: RiBVD Every cycle: |
Completed |
Study Name: Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2007-12-21 Interventions: Procedure: Intensive Induction-BMT Patients will undergo an induction regimen consisting of 1 cycle of c |
Not yet recruiting |
Study Name: The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-10-11 Interventions:
|
Recruiting |
Study Name: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Condition: Mantle-Cell Lymphoma Date: 2009-04-07 Interventions:
|
Completed |
Study Name: Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2005-07-07 Interventions:
|
Completed |
Study Name: Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2008-03-04 Interventions:
|
Completed |
Study Name: Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) Condition: Mantle Cell Lymphoma Date: 2007-07-20 Interventions: Drug: Y-90 Ibritumomab tiuxetan Study Design |
Completed |
Study Name: A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy Condition: Mantle Cell Lymphoma Date: 2012-05-14 Interventions: Drug: Ibrutinib Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibruti |
Active, not recruiting |
Study Name: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Condition: Mantle Cell Lymphoma Date: 2009-08-20 Interventions:
|
Completed |
Study Name: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Condition: Mantle Cell Lymphoma Date: 2012-07-18 Interventions:
|